Dropping The 52 Week Low, CELLECT BIOTECH/S ADR (Nasdaq:APOP) Closing Trading At $3.08

0
7
Car Wreck freeimages.com/dimitri_c
Car Wreck freeimages.com/dimitri_c

CELLECT BIOTECH/S ADR (Nasdaq:APOP)

December 6th, 2018
CELLECT BIOTECH/S ADR finished Thursday’s trading session down 5.81%, a $0.19 decrease to close on $3.08. As well as the drop in value, CELLECT BIOTECH/S ADR hit a new 52 week low of $3.00, breaking the previous low of $3.04 from earlier this July. CELLECT BIOTECH/S ADR swung 12.33% between high and low. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the recommended threshold of 1.8%, and calculated to be -1.39.

APOP was outperformed by the rest of the Healthcare sector which went down just 0.31%.

Market Sectors

The market sectors were mixed Thursday with a majority of the sectors trending down. Real Estate saw the biggest increase of the day (2.66%), while Energy saw the biggest drop (1.77%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector dropping 13%.

Communication Services saw the biggest turnaround from its 5-day performance of -0.23%, as it went up 1.04%. Energy and Materials saw turn arounds from their five day positive performance, Energy with a drop of 1.77%.

Sector Breakdown

  • Real Estate went up with a 2.66% change.
  • Communication Services went up with a 1.04% change.
  • Consumer Discretionary went up with a 0.61% change.
  • Information Technology went up with a 0.23% change.
  • Utilities went down with a -0.10% change.
  • Consumer Staples went down with a -0.10% change.
  • Healthcare went down with a -0.31% change.
  • Industrials went down with a -0.55% change.
  • Materials went down with a -1.36% change.
  • Financials went down with a -1.44% change.
  • Energy went down with a -1.77% change.

CELLECT BIOTECH/S ADR Info

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that CELLECT BIOTECH/S ADR’s score is -1.39) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

APOP daily update
APOP daily update


Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.